Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Klotho Neurosciences ( (KLTO) ).
On March 2, 2026, Klotho Neurosciences, Inc. closed a private placement financing under a February 19, 2026 securities purchase agreement, issuing 34,551,939 shares of common stock and an equal number of warrants to accredited investors. The transaction, conducted under an exemption from Securities Act registration and without general solicitation, generated approximately $7.75 million in gross proceeds, bolstering the company’s capital base and financial flexibility.
The purchasers represented that they acquired the securities for investment purposes, reinforcing the targeted nature of the fundraising among sophisticated investors. This financing structure, pairing common stock with warrants, may influence future capital raising dynamics and potential dilution while supporting Klotho Neurosciences’ ongoing operational and strategic needs.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. operates in the biopharmaceutical sector, focusing on developing neuroscience-related therapies and products. The company raises capital through equity and warrant offerings aimed at funding its research, development, and corporate activities within the life sciences and neurology markets.
Average Trading Volume: 1,810,334
Technical Sentiment Signal: Buy
Current Market Cap: $39.09M
For detailed information about KLTO stock, go to TipRanks’ Stock Analysis page.